LEADER 03717nam  2200637 a 450 
001 9910437619503321
005 20200520144314.0
010   $a3-0348-0664-7
024 7 $a10.1007/978-3-0348-0664-0
035   $a(CKB)2670000000406493
035   $a(EBL)1398543
035   $a(SSID)ssj0000958079
035   $a(PQKBManifestationID)11485126
035   $a(PQKBTitleCode)TC0000958079
035   $a(PQKBWorkID)10986112
035   $a(PQKB)10336833
035   $a(DE-He213)978-3-0348-0664-0
035   $a(MiAaPQ)EBC1398543
035   $a(PPN)172421926
035   $a(EXLCZ)992670000000406493
100   $a20130529d2013      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aTamoxifen $epioneering medicine in breast cancer /$fPhilipp Y. Maximov, Russell E. McDaniel, V. Craig Jordan
205   $a1st ed. 2013.
210   $aBasel $cSpringer$d2013
215   $a1 online resource (218 p.)
225  0$aMilestones in drug therapy
300   $aDescription based upon print version of record.
311   $a3-0348-0783-X 
311   $a3-0348-0663-9 
320   $aIncludes bibliographical references.
327   $aDiscovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens -- Tamoxifen Goes Forward Alone -- Metabolites of Tamoxifen as the Basis of Drug Development -- Adjuvant Therapy ? The Breakthrough -- The Wisconsin Story in the 1980?s: Discovery of Target Site Specific Estrogen Action -- Carcinogenesis and Tamoxifen -- Chemoprevention: Cinderella waiting for the ball -- Tamoxifen and Raloxifene head to head: The STAR TRIAL -- Acquired resistance to Tamoxifen: back to the beginning -- The legacy of Tamoxifen -- Appendix: Four decades of discovery in breast cancer research and treatment ? an interview with V. Craig Jordan by Marc Poirot -- Selected Awards that Recognize the Contribution of Tamoxifen and Raloxifene to Medicine.
330   $aTamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the ?father of tamoxifen? - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a ?failed morning after contraceptive? to become the ?gold standard? for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen?s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.
410  0$aMilestones in Drug Therapy,$x2296-6056
606   $aTamoxifen
606   $aBreast$xCancer$xChemoprevention
606   $aBreast$xCancer$xChemotherapy
615  0$aTamoxifen.
615  0$aBreast$xCancer$xChemoprevention.
615  0$aBreast$xCancer$xChemotherapy.
676   $a616.99449061
676   $a616.99449061
700   $aMaximov$b Philipp Y$01065515
701   $aJordan$b V. Craig$g(Virgil Craig)$01759158
701   $aMcDaniel$b Russell E$01759159
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910437619503321
996   $aTamoxifen$94197526
997   $aUNINA